DELTICOM-AG/YOURTYRES
13.10.2016 12:09:02 CEST | Business Wire | Press release
They’re technological milestones with cult status and are now in high demand: modern classics. Lovers of the Saab 900, the Ford Granada, the Audi 80 and co. place great importance on maintaining their vehicles as true to the original condition as possible. This applies in particular to parts that are prone to wear, such as tyres. Sooner or later they have to be replaced, as even with low mileage they age, harden and eventually crack. “An opportunity for tyre dealers and workshops: even businesses that don’t specialise in classic cars or modern classics can capture the cult vehicle fan target group”, explains Andreas Faulstich, Head of B2B at Delticom, Europe’s largest online tyre retailer, and parent company to the online shop for dealers,Yourtyres.co.uk . “It’s impossible for one retailer to stock absolutely every model and dimension of tyre for historical cars. This is where Yourtyres.co.uk’s retail partnership model comes into play, effectively binding online and offline trade together in a way that is profitable for both sides.”
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161013005602/en/
Yourtyres.co.uk offers a wide range of historical tyre models and dimensions that today are produced to meet current standards by many well-known manufacturers, for example the “Sprint Classic” by Vredestein, or Maxxi’s “MA 1”. Exclusive to Delticom’s dealer shop, commercial customers can get their hands on the “Retro Classic 001” by Retro, a classic car tyre offering a great price-performance ratio, produced in-house by Nankang and also available as a whitewall tyre.
Searching for the perfect tyre is quick and easy. Prospective buyers can search by tyre dimension or vehicle model. Thanks to its own stock holding and consequent high availability, commercial customers also benefit from one of Yourtyres.co.uk ’s greatest strengths: its flexibility. Delivery times are short, and shipping is free from the very first tyre. If you need advice, you can contact Delticom’s experienced B2B Services team via email or by phone. Consultants are available from 7am to 10pm Monday to Friday, above and beyond normal business hours. Favourable purchase prices also allow partners of Delticom B2B and Yourtyres.co.uk to achieve attractive margins.
“We want to enable dealers and workshops to increase their end-user reach. Distributing historical tyre models is a great way to do this. Another way to increase your reach even further is to register as a fitting partner for Yourtyres.co.uk free of charge. This provides businesses with the potential to benefit from each and every online purchase in one of our end-customer shops”, expands Faulstich. “In addition to tyre fitting, further services can be connected to workshops or retail outlets, enabling an expansion of the business.”
About Yourtyres.co.uk
Yourtyres.co.uk de is the exclusive online store from Delticom AG for workshops, retailers, wholesalers, tyre fitters/service stations and car accessories. With over 15 years’ expertise in the online tyre business, the Yourtyres.co.uk specialist B2B team offers its clients a spectacular range of car and motorbike tyres of all brands and dimensions for all types of vehicles, tyres for light trucks, trucks and buses, custom tyres, complete wheel sets, car spare parts and accessories, engine oil and batteries. In addition to favourable purchasing conditions, retail clients benefit from the online shop’s time-saving tyre search function, high availability, reliable delivery thanks to in-house warehouses, as well as a simple registration process with no hidden costs - from the very first tyre.
Online shop for dealers and workshops in the UK: www.yourtyres.co.uk and 24 further countries.
Information about the company : www.delti.com
Tyre tests : www.tyretest.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161013005602/en/
Contact:
insignis Agentur für
Kommunikation GmbH (GPRA)
Henning Jahns
Tel.:
+49-511-132214-14
Fax: +49-511-132214-99
delticom@insignis.de
or
Delticom
AG
Anne Lena Peters
Tel.: +49-511-93634-8909
Fax:
+49-511-93634-8301
anne.lena.peters@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom